Can HPV-16 genotyping provide a benchmark for cervical biopsy specimen interpretation?

Mary T. Galgano, Philip E. Castle, Mark H. Stoler, Diane Solomon, Mark Schiffman

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Human papillomavirus (HPV) detection is an objective quality assurance benchmark for cervical cytology. There is no comparable metric for cervical biopsies despite biopsies having similar interobserver variability. Because HPV-16 positivity increases with the severity of cervical abnormality, we explored whether HPV-16 detection might be a useful metric for distinguishing a diagnosis of less than cervical intraepithelial neoplasia (CIN) 2 from CIN 2 or worse (representing the clinical threshold for treatment). By using Atypical Squamous Cells of Undetermined Significance - Low-Grade Squamous Intraepithelial Lesion Triage Study data, we compared biopsy diagnoses of the 10 clinical center (CC) pathologists with the quality control (QC) group. Although the percentage of HPV-16 correlated with severity of diagnoses, there was great variability between the rates for each individual CC pathologist. Agreement between individual CC pathologists and the QC group on the percentage of CIN 2 or worse containing HPV-16 correlated weakly with agreement on whether the diagnosis was less than CIN 2 or CIN 2 or worse. Thus the HPV-16 fraction was not found to be broadly useful as a quality assurance metric for biopsy diagnosis in this analysis.

Original languageEnglish (US)
Pages (from-to)65-70
Number of pages6
JournalAmerican Journal of Clinical Pathology
Volume130
Issue number1
DOIs
StatePublished - Jul 2008
Externally publishedYes

Fingerprint

Benchmarking
Cervical Intraepithelial Neoplasia
Human papillomavirus 16
Biopsy
Quality Control
Control Groups
Observer Variation
Triage
Cell Biology
Pathologists

Keywords

  • Benchmark
  • Biopsy
  • Cervical intraepithelial neoplasia
  • Colposcopy
  • HPV
  • Human papillomavirus
  • Quality assurance

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Can HPV-16 genotyping provide a benchmark for cervical biopsy specimen interpretation? / Galgano, Mary T.; Castle, Philip E.; Stoler, Mark H.; Solomon, Diane; Schiffman, Mark.

In: American Journal of Clinical Pathology, Vol. 130, No. 1, 07.2008, p. 65-70.

Research output: Contribution to journalArticle

Galgano, Mary T. ; Castle, Philip E. ; Stoler, Mark H. ; Solomon, Diane ; Schiffman, Mark. / Can HPV-16 genotyping provide a benchmark for cervical biopsy specimen interpretation?. In: American Journal of Clinical Pathology. 2008 ; Vol. 130, No. 1. pp. 65-70.
@article{c0f7f0a7923f4483889fe37c3d744717,
title = "Can HPV-16 genotyping provide a benchmark for cervical biopsy specimen interpretation?",
abstract = "Human papillomavirus (HPV) detection is an objective quality assurance benchmark for cervical cytology. There is no comparable metric for cervical biopsies despite biopsies having similar interobserver variability. Because HPV-16 positivity increases with the severity of cervical abnormality, we explored whether HPV-16 detection might be a useful metric for distinguishing a diagnosis of less than cervical intraepithelial neoplasia (CIN) 2 from CIN 2 or worse (representing the clinical threshold for treatment). By using Atypical Squamous Cells of Undetermined Significance - Low-Grade Squamous Intraepithelial Lesion Triage Study data, we compared biopsy diagnoses of the 10 clinical center (CC) pathologists with the quality control (QC) group. Although the percentage of HPV-16 correlated with severity of diagnoses, there was great variability between the rates for each individual CC pathologist. Agreement between individual CC pathologists and the QC group on the percentage of CIN 2 or worse containing HPV-16 correlated weakly with agreement on whether the diagnosis was less than CIN 2 or CIN 2 or worse. Thus the HPV-16 fraction was not found to be broadly useful as a quality assurance metric for biopsy diagnosis in this analysis.",
keywords = "Benchmark, Biopsy, Cervical intraepithelial neoplasia, Colposcopy, HPV, Human papillomavirus, Quality assurance",
author = "Galgano, {Mary T.} and Castle, {Philip E.} and Stoler, {Mark H.} and Diane Solomon and Mark Schiffman",
year = "2008",
month = "7",
doi = "10.1309/A8MFC18TWANC8QFH",
language = "English (US)",
volume = "130",
pages = "65--70",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "1",

}

TY - JOUR

T1 - Can HPV-16 genotyping provide a benchmark for cervical biopsy specimen interpretation?

AU - Galgano, Mary T.

AU - Castle, Philip E.

AU - Stoler, Mark H.

AU - Solomon, Diane

AU - Schiffman, Mark

PY - 2008/7

Y1 - 2008/7

N2 - Human papillomavirus (HPV) detection is an objective quality assurance benchmark for cervical cytology. There is no comparable metric for cervical biopsies despite biopsies having similar interobserver variability. Because HPV-16 positivity increases with the severity of cervical abnormality, we explored whether HPV-16 detection might be a useful metric for distinguishing a diagnosis of less than cervical intraepithelial neoplasia (CIN) 2 from CIN 2 or worse (representing the clinical threshold for treatment). By using Atypical Squamous Cells of Undetermined Significance - Low-Grade Squamous Intraepithelial Lesion Triage Study data, we compared biopsy diagnoses of the 10 clinical center (CC) pathologists with the quality control (QC) group. Although the percentage of HPV-16 correlated with severity of diagnoses, there was great variability between the rates for each individual CC pathologist. Agreement between individual CC pathologists and the QC group on the percentage of CIN 2 or worse containing HPV-16 correlated weakly with agreement on whether the diagnosis was less than CIN 2 or CIN 2 or worse. Thus the HPV-16 fraction was not found to be broadly useful as a quality assurance metric for biopsy diagnosis in this analysis.

AB - Human papillomavirus (HPV) detection is an objective quality assurance benchmark for cervical cytology. There is no comparable metric for cervical biopsies despite biopsies having similar interobserver variability. Because HPV-16 positivity increases with the severity of cervical abnormality, we explored whether HPV-16 detection might be a useful metric for distinguishing a diagnosis of less than cervical intraepithelial neoplasia (CIN) 2 from CIN 2 or worse (representing the clinical threshold for treatment). By using Atypical Squamous Cells of Undetermined Significance - Low-Grade Squamous Intraepithelial Lesion Triage Study data, we compared biopsy diagnoses of the 10 clinical center (CC) pathologists with the quality control (QC) group. Although the percentage of HPV-16 correlated with severity of diagnoses, there was great variability between the rates for each individual CC pathologist. Agreement between individual CC pathologists and the QC group on the percentage of CIN 2 or worse containing HPV-16 correlated weakly with agreement on whether the diagnosis was less than CIN 2 or CIN 2 or worse. Thus the HPV-16 fraction was not found to be broadly useful as a quality assurance metric for biopsy diagnosis in this analysis.

KW - Benchmark

KW - Biopsy

KW - Cervical intraepithelial neoplasia

KW - Colposcopy

KW - HPV

KW - Human papillomavirus

KW - Quality assurance

UR - http://www.scopus.com/inward/record.url?scp=48249092101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48249092101&partnerID=8YFLogxK

U2 - 10.1309/A8MFC18TWANC8QFH

DO - 10.1309/A8MFC18TWANC8QFH

M3 - Article

C2 - 18550472

AN - SCOPUS:48249092101

VL - 130

SP - 65

EP - 70

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 1

ER -